Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Gastrointestinal 1CNS 1

Conditions

Neoplasms 1Leukemia, Myeloid, Acute 1Glioma 1Cholangiocarcinoma 1

Interventions

Temozolomide 43Magnetic Resonance Spectroscopy 39Specimen Handling 28Radiotherapy 19Radiation 16Bevacizumab 13Radiosurgery 12Nivolumab 12Biopsy 12X-Rays 10Cyclophosphamide 9Carboplatin 9Nuclear Medicine Department, Hospital 7Lomustine 7Irinotecan 7pembrolizumab 6Ipilimumab 6Cisplatin 6AZD 6244 6Vincristine 5Topotecan 5Phantoms, Imaging 5Etoposide 5CTLA-4 Antigen 5ulixertinib 4trametinib 4olaparib 4erdafitinib 4dinutuximab 4binimetinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cytochrome P-450 CYP2C19 × CNS × 30 days × Clear all
NCT07486713 2026-06-05

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

Rigel Pharmaceuticals

Phase 4 Recruiting
16 enrolled
CNSGastrointestinalOther hematologic neoplasm

Glioma, Neoplasms, Leukemia, Myeloid, Acute, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡